Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck's Branded Generics Will Play A Supplementary, Country-specific Role

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Merck is putting into play a branded generics business strategy that involves extracting value out of a large set of its off-patented drugs through an aggressive push into developing markets, where the "lifecycle value of its brands" is significantly higher as compared to developed markets

You may also be interested in...



Post-merger MSD To Begin Rollout Of Merck and Schering-Plough Legacy Products In Japan

TOKYO - Merck, previously operating in Japan via majority-held Banyu Pharmaceutical, will merge with Schering-Plough Japan Oct. 1 under the new title MSD; the combined company expects to vault into the rankings of the top three pharmaceutical firms in Japan thanks to constant rollout of new products in the near-term future

Post-merger MSD To Begin Rollout Of Merck and Schering-Plough Legacy Products In Japan

TOKYO - Merck, previously operating in Japan via majority-held Banyu Pharmaceutical, will merge with Schering-Plough Japan Oct. 1 under the new title MSD; the combined company expects to vault into the rankings of the top three pharmaceutical firms in Japan thanks to constant rollout of new products in the near-term future

"We Want To Shape Up Medical Treatment Paradigm Through Partnerships," Says Merck Asia-Pac President Ramesh Subrahmanian: An Interview With PharmAsia News (Part 2 of 2)

Merck Asia Pacific President of Human Health Ramesh Subrahmanian has been among the most energetic executives to have worked in the Indian pharmaceutical industry. Prior to serving in his present responsibilities, Subrahmanian worked for Sanofi-Aventis in several senior capacities - one of which was to head the company's Indian operations in 2000.

Latest News
See All
UsernamePublicRestriction

Register

SC075645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel